Cinchona
5 benefits mapped to clinical evidence across supplements.
Benefit Evidence
Parasite clearance, fever ↓
Higher cure, blood levels
Rectal bioavailability 36–62%
Parasite clearance, fever ↓
Higher cure, blood levels
Rectal bioavailability 36–62%
Research sources
Cold/flu relief (5)
- Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria
PubMed ID: 12610739
PK comparison found intrarectal cinchona provided clinically adequate exposure and all children aparasitaemic at 72 h.
- [Diluted injectable quinine in the intramuscular and intrarectal route: comparative efficacity and tolerance in malaria treatment for children ]
PubMed ID: 12192713
Trial showed intrarectal diluted injectable quinine equally effective to IM by 72 h (parasite/febrile outcomes).
- Reducing the oral quinine-quinidine-cinchonin (Quinimax) treatment of uncomplicated malaria to three days does not increase the recurrence of attacks among children living in a highly endemic area of Senegal
PubMed ID: 8761582
Large series in children: 3-day oral cinchona-containing regimen produced high clinical efficacy and fever/clinical improvement.
- Dose-dependent resorption of quinine after intrarectal administration to children with moderate Plasmodium falciparum malaria
PubMed ID: 15504872
Dose-ranging PK study defined IR doses approximating parenteral exposure with implications for clinical parasite/fever control.
- An open randomized clinical study of intrarectal versus infused Quinimax for the treatment of childhood cerebral malaria in Niger
PubMed ID: 9850403
Open randomized severe (cerebral) malaria trial: intrarectal Quinimax had comparable recovery/mortality and clinical parasite clearance.
Gut health (5)
- Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria
PubMed ID: 12610739
Intrarectal cinchona produced adequate exposure and complete parasite clearance by 72 h in children.
- [Diluted injectable quinine in the intramuscular and intrarectal route: comparative efficacity and tolerance in malaria treatment for children ]
PubMed ID: 12192713
Both IR and IM administration resulted in aparasitaemia by 72 h, supporting antiparasitic effectiveness.
- An open randomized clinical study of intrarectal versus infused Quinimax for the treatment of childhood cerebral malaria in Niger
PubMed ID: 9850403
Severe malaria trial showed similar clinical parasite clearance and outcomes with intrarectal formulation.
- Reducing the oral quinine-quinidine-cinchonin (Quinimax) treatment of uncomplicated malaria to three days does not increase the recurrence of attacks among children living in a highly endemic area of Senegal
PubMed ID: 8761582
Three-day oral cinchona-containing regimen achieved high clinical efficacy in endemic pediatric population (antiparasitic effect).
- Dose-dependent resorption of quinine after intrarectal administration to children with moderate Plasmodium falciparum malaria
PubMed ID: 15504872
PK work demonstrated IR dosing strategies that approximate parenteral exposure for parasite clearance.
Appetite regulation (2)
- Gengricin(®): A Nutraceutical Formulation for Appetite Control and Therapeutic Weight Management in Adults Who Are Overweight/Obese
PubMed ID: 38473841
Cinchona-containing products reduced food cravings and preserved CCK, with greater weight/fat loss—strong appetite-related evidence.
- The Effects of a Cinchona Supplementation on Satiety, Weight Loss and Body Composition in a Population of Overweight/Obese Adults: A Controlled Randomized Study
PubMed ID: 38140292
Maintained CCK and increased satiety vs placebo in overweight adults, directly supporting appetite suppression/satiety.
Metabolism (2)
- Gengricin(®): A Nutraceutical Formulation for Appetite Control and Therapeutic Weight Management in Adults Who Are Overweight/Obese
PubMed ID: 38473841
Double-blind RCT of cinchona-containing nutraceuticals produced greater weight and fat loss vs placebo.
- The Effects of a Cinchona Supplementation on Satiety, Weight Loss and Body Composition in a Population of Overweight/Obese Adults: A Controlled Randomized Study
PubMed ID: 38140292
Randomized supplement trial showed significant weight, BMI and fat-mass reductions alongside preserved CCK (metabolic effects).
Inflammation (1)
- Glycyrrhizin alleviates the toxicity of hydroxychloroquine in treating oral lichen planus by occupying heat shock protein 90 alpha
PubMed ID: 39550918
HCQ (quinine-derivative) showed anti-inflammatory benefit for oral lichen planus versus prednisone; indirect evidence for inflammatory comfort.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Cinchona
Search all22 products whose verified label declares Cinchona — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.